CN103525639B - A kind of wine containing Pyrroloquinoline quinone - Google Patents
A kind of wine containing Pyrroloquinoline quinone Download PDFInfo
- Publication number
- CN103525639B CN103525639B CN201310499832.8A CN201310499832A CN103525639B CN 103525639 B CN103525639 B CN 103525639B CN 201310499832 A CN201310499832 A CN 201310499832A CN 103525639 B CN103525639 B CN 103525639B
- Authority
- CN
- China
- Prior art keywords
- wine
- pyrroloquinoline quinone
- mouse
- liver
- gavage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention provides a kind of wine containing Pyrroloquinoline quinone, this wine comprises following component and content: Pyrroloquinoline quinone 0.01% ~ 10%, stablizer 0.01% ~ 1%, solubility promoter 0.01% ~ 1%, wine 88% ~ 99.9%.Wine containing Pyrroloquinoline quinone of the present invention it can specificity prevention alcoholic fatty liver, suppress the process of disease, there are good market outlook.
Description
Technical field
The present invention relates to a kind of health promoting beverage, be specifically related to a kind of wine that can prevent fatty liver containing Pyrroloquinoline quinone.
Background technology
Chinese drink the history having more than 5000.Present stage, the Drinking rate of China's population is 59.5%, and wherein the male sex is 84.6%, and women is 29.4%, and drinking amount is 3.6L straight alcohol year per capita.By epidemiology survey, the Drinking rate such as the good government functionary of economic situation, businessman, soldier are the highest, and the male sex is all higher than women.
Alcohol has obvious toxic action to liver: after ethanol enters liver cell, and the oxidation through a series of enzyme is acetaldehyde.Excessive consumption of alcohol, a large amount of acetaldehyde has obvious toxic action to liver cell, directly or indirectly causes hepatocellular degeneration, necrosis and fibrosis, can develop into liver cirrhosis time serious.A series of pathologies such as the liver damage caused due to Excess free enthalpy alcohol are called as alcoholic liver disease (alcoholicliverdisease, ALD).ALD to be divided into light-duty ALD, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis 5 type according to the pathological change of alcoholic liver disease by hepatology branch of Chinese Medical Association.
In the U.S., ALD occupies the 10th in the cause of the death, has 1.5 ~ 20,000 people to die from ALD every year.Only 1994, the medical expense that the U.S. pays because of ALD just exceeded 2,500,000,000 dollars.Britain is every year because of liver cirrhosis and chronic hepatopathy died about 3000 example, and wherein about 1200 examples are ALD.In recent years, along with the improvement of living condition, ALD also has the trend increased in China.According to domestic clinical criteria, essence of drinking day amount (closes 50 degree of white wine 100 milliliters, about 2 liang) more than 40 grams, and the patient of continuous more than 5 years is alcoholist, and in these crowds, more than 48% suffers from alcoholic liver disease in various degree.Drinking-associated has become large medical science and the social concern that China faces, and alcoholic liver disease also more and more causes the concern of people.
Summary of the invention
For the problems referred to above, the invention provides a kind of wine that can prevent alcoholic fatty liver.
For achieving the above object, the present invention adopts following technical scheme:
The invention provides a kind of wine containing Pyrroloquinoline quinone.
Above-mentioned wine comprises following component and content: Pyrroloquinoline quinone 0.01% ~ 10%, stablizer: 0.01% ~ 1%, solubility promoter 0.01% ~ 1%, wine 88% ~ 99.9%.
Be preferably, this wine comprises following component and content: Pyrroloquinoline quinone 0.1% ~ 1%, stablizer: 0.1 ~ 0.5%, solubility promoter 0.1% ~ 0.5%, wine 98% ~ 99.7%.
Be more preferably, this wine comprises following component and content: Pyrroloquinoline quinone 0.5%, stablizer: 0.2%, solubility promoter 0.2%, wine 99.1%.
Aforementioned stable agent includes but not limited to lactose, sucrose, mannitol, glucose, mannitol, Microcrystalline Cellulose etc.
Above-mentioned solubility promoter includes but not limited to L-glutamic acid, glycine, glutamine, arginine etc.
Above-mentioned wine includes but not limited to white wine, beer, fruit wine, yellow rice wine etc.
Containing Pyrroloquinoline quinone in wine provided by the invention, Pyrroloquinoline quinone is the prothetic group of multiple enzyme in bacterium, and can affect the level of respiratory chain function and interior free yl.Pyrroloquinoline quinone in the present invention has following physiological function: (1) is anti-oxidant; (2) liver injury that contratoxin causes plays protective effect; (3) degraded to ethanol is accelerated; (4) nerve growth effect is promoted.Visible, Pyrroloquinoline quinone can block several approach that fatty liver is formed.
Pyrroloquinoline quinone in the present invention when continuing to drink, can suppress the change AST of multiple enzyme in course of liver damage, ALT ..., then reverse the morphological change of fatty liver.Visible, the wine containing Pyrroloquinoline quinone of the present invention it can specificity prevention alcoholic fatty liver, suppress the process of disease, there are good market outlook.
Embodiment
Following examples are used for further illustrating content of the present invention, but should not be construed as limitation of the present invention.Without departing from the spirit and substance of the case in the present invention, the amendment do the inventive method, step or condition or replacement, all belong to scope of the present invention.
The percentage sign " % " related in the present invention, if not specified, refers to mass percent.
Embodiment 1 is containing the preparation of Pyrroloquinoline quinone wine
The preparation of Pyrroloquinoline quinone is specifically see Chinese patent 02111549.4.By GCpqq303 bacterial strain at substratum (0.3% (NH
4)
2sO
4, 0.14%KH
2pO
4, 0.01%MgSO
4, 0.05%FeCl
3, 0.8% methyl alcohol), cultivate 14 days for 30 degrees Celsius.Carry out more than three times to express, obtainable expression amount about 3 ~ 4mg/l.
Fermented liquid supernatant, through boiling, is adsorbed in after centrifuging on FPLC-Q post, and through salt gradient elution, collects Peak Activity.The Pyrroloquinoline quinone obtained detects through FPLC method, and purity is more than 90%, and yield is 56%.
Embodiment 2 contains the wine of Pyrroloquinoline quinone to the prophylactic effect of fatty liver
Kunming mice is divided into 6 groups, often organize 12, male and female half and half, mean body weight is 25g, to the wine of each group of gavage containing the Pyrroloquinoline quinone of different amount.Concrete gavage grouping is in table 1:
Table 1: the concrete composition of each test group gavage
| Group | Pyrroloquinoline quinone | Sucrose | L-glutamic acid |
| Test group 1 | 0.1g | 0.1g | 0.1g |
| Test group 2 | 1g | 1g | 1g |
| Test group 3 | 5g | 2g | 2g |
| Test group 4 | 10g | 5g | 5g |
| Test group 5 | 20g | 5g | 5g |
Pyrroloquinoline quinone in each test group in upper table, sucrose, L-glutamic acid are dissolved in respectively in 1L white wine (40 degree) and make 5 groups of wine containing the Pyrroloquinoline quinones of different amount, and be that the test group of common white spirit is set to control group by gavage.
The wine of above-mentioned 6 test group is given respectively 12 mouse stomaches often in group, the amount of gavage is every 0.25ml/ days, carries out 15 days continuously.After experimentation on animals terminates, get mouse liver, liver, through paraffin section, after dyeing, observes the physiological change of liver organization.
Find after each group of mouse liver section statining, a large amount of cavity has been there is around the nucleus of the mouse liver of control group, and the mouse in test group 1 has only had 3 to occur a small amount of cavity, test in 2 groups and have a mouse to observed several cavity, mouse in other groups does not all observe cavity, the amount of the visible Pyrroloquinoline quinone reached in test group 3 just effectively can prevent fatty liver, test group 4 and 5 is the test group of the amount strengthening Pyrroloquinoline quinone again, result, the effect of its prevention fatty liver does not occur to promote significantly compared with test group 3 yet, but the production cost of two groups rises many.Therefore, after considering production cost, visible test group 3 is best selection schemes.The above results can show, the wine containing Pyrroloquinoline quinone has certain prophylactic effect to fatty liver.
Embodiment 3 dissimilar containing the wine of Pyrroloquinoline quinone to the prophylactic effect of fatty liver
Choose the Kaoliang spirit of the identical number of degrees (40 degree), corn wine, white wine, red wine, yellow rice wine, beer six kinds of wine, get above-mentioned 6 kinds of each 1L of wine kind, add Pyrroloquinoline quinone 0.1g, sucrose 0.1g, L-glutamic acid 0.1g respectively as test group 1; Pyrroloquinoline quinone 1g, sucrose 1g, L-glutamic acid 1g is added respectively as test group 2 in above-mentioned 6 kinds of wine.
The wine of above-mentioned 2 test group is given respectively 72 mouse stomaches (often kind of wine gavage mouse is 12) often in group, the amount of gavage is every 0.25ml/ days, carries out 15 days continuously.After experimentation on animals terminates, get mouse liver, liver, through paraffin section, after dyeing, observes the physiological change of liver organization.
Find after the section statining of test group 1 mouse liver, 12 mouse of Kaoliang spirit gavage a small amount of cavity that had 4 to occur, the mouse of corn wine gavage a small amount of cavity that also had 4 to occur, 3 are had to occur cavity in 12 mouse of white wine gavage, and the mouse of red wine gavage only has 2 to occur cavity, there is cavity in the mouse 3 of yellow rice wine gavage, the mouse of beer gavage is also 4 and has occurred cavity.
Find after testing 2 groups of mouse liver section statinings, 12 mouse of Kaoliang spirit gavage a small amount of cavity that had 1 to occur, the mouse of corn wine gavage a small amount of cavity that also had 1 to occur, 1 is had to occur cavity in 12 mouse of white wine gavage, and all there is not cavity in all mouse of red wine gavage, there is not the mouse of cavity in the mouse of yellow rice wine gavage, the mouse of beer gavage is also 1 and has occurred cavity yet.
The above results shows, adds the Pyrroloquinoline quinone of same amount in different types of wine, and institute plays and prevents the effect of fatty liver and be not quite similar, and the effect of some wine will obviously be better than other wine.Visible, some beneficiating ingredient in the Pyrroloquinoline quinone of interpolation and wine plays complementary effect.
The stability of embodiment 3 Pyrroloquinoline quinone in wine
Continue to deposit the above-mentioned wine adding Pyrroloquinoline quinone after embodiment 2 completes, the content of Pyrroloquinoline quinone in various wine in active electrophoresis method experiment with measuring group 2 is used in the test just terminated in embodiment 2 afterwards, experimental result shows, the Pyrroloquinoline quinone in wine is not degraded.Place after 1,3,6,12,24 month and continue to measure above-mentioned various wine, the pyrroloquinoline quinone content in the various wine of test group 2 does not all change, and result shows, Pyrroloquinoline quinone is highly stable in wine.
Claims (6)
1., containing a wine for Pyrroloquinoline quinone, it is characterized in that, this wine is made up of following component and content: Pyrroloquinoline quinone 0.01% ~ 10%, stablizer 0.01% ~ 1%, solubility promoter 0.01% ~ 1%, wine 88% ~ 99.9%.
2. wine according to claim 1, is characterized in that, this wine is made up of following component and content: Pyrroloquinoline quinone 0.1% ~ 1%, stablizer 0.1 ~ 0.5%, solubility promoter 0.1% ~ 0.5%, wine 98% ~ 99.7%.
3. wine according to claim 1 and 2, is characterized in that, this wine is made up of following component and content: Pyrroloquinoline quinone 0.5%, stablizer 0.2%, solubility promoter 0.2%, wine 99.1%.
4. wine according to claim 1 and 2, is characterized in that, aforementioned stable agent is selected from lactose, sucrose, mannitol, glucose or Microcrystalline Cellulose.
5. wine according to claim 4, is characterized in that, above-mentioned solubility promoter is selected from L-glutamic acid, glycine, glutamine or arginine.
6. wine according to claim 5, is characterized in that, above-mentioned wine is selected from white wine, beer, fruit wine or yellow rice wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310499832.8A CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310499832.8A CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103525639A CN103525639A (en) | 2014-01-22 |
| CN103525639B true CN103525639B (en) | 2015-09-16 |
Family
ID=49927994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310499832.8A Expired - Fee Related CN103525639B (en) | 2013-10-22 | 2013-10-22 | A kind of wine containing Pyrroloquinoline quinone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103525639B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7167911B2 (en) * | 2017-03-28 | 2022-11-09 | 三菱瓦斯化学株式会社 | Pyrroloquinoline quinone-containing jelly |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454595A (en) * | 2002-04-29 | 2003-11-12 | 上海医学生命科学研究中心有限公司 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
| CN1939403A (en) * | 2005-09-26 | 2007-04-04 | 孙毅 | Production of compound Danshen root injection |
| CN101278907A (en) * | 2008-05-28 | 2008-10-08 | 喻文涛 | Coenzyme Q10 injection |
| CN101889978A (en) * | 2010-04-29 | 2010-11-24 | 袁璐 | Pharmaceutical composition containing vinpocetine, preparation method and application thereof |
| JP2011024476A (en) * | 2009-07-24 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Pyrroloquinolinequinone-containing alcohol |
-
2013
- 2013-10-22 CN CN201310499832.8A patent/CN103525639B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454595A (en) * | 2002-04-29 | 2003-11-12 | 上海医学生命科学研究中心有限公司 | Pharmaceutical composition comprising pyrroloquinoline quinone for curing and preventing fatty liver |
| CN1939403A (en) * | 2005-09-26 | 2007-04-04 | 孙毅 | Production of compound Danshen root injection |
| CN101278907A (en) * | 2008-05-28 | 2008-10-08 | 喻文涛 | Coenzyme Q10 injection |
| JP2011024476A (en) * | 2009-07-24 | 2011-02-10 | Mitsubishi Gas Chemical Co Inc | Pyrroloquinolinequinone-containing alcohol |
| CN101889978A (en) * | 2010-04-29 | 2010-11-24 | 袁璐 | Pharmaceutical composition containing vinpocetine, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103525639A (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110621329B (en) | Use of plant extracts for preparing composition for protecting cardiovascular system | |
| CN102994305B (en) | Method for preparing health-care food (therapy) product (nutrient juice wine) by use of extracts from cordyceps militaris and cocoon | |
| CN103651151A (en) | Fungus for promoting aquilaria plants to generate agilawood and application of fungus | |
| US9717766B2 (en) | Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof | |
| CN103859082B (en) | Gold flower big red robe tea and processing technology thereof | |
| CN103555641A (en) | Mycoplasma hyopneumoniae culture medium and preparation method thereof | |
| CN104522812B (en) | A kind of Cordyceps sinensis viable bacteria beverage and production method thereof | |
| CN104987316A (en) | Marine fungus-derived polyketone compound and application thereof in treatment of type 2 diabetes | |
| CN103525639B (en) | A kind of wine containing Pyrroloquinoline quinone | |
| CN103948023A (en) | Health foods for enhancing immunity and improving sleep and two-step fermentation preparation method thereof | |
| KR101799400B1 (en) | Medium composition comprising amino acids for sparassis latifolia mycelium and the production method of the sparassis latifolia mycelium with improved gamma-amino butyrate using the same | |
| US9867851B2 (en) | Food for nutritional therapy of AIDS | |
| CN102987501B (en) | Method for preparing nutrient (liquid) beverages and granules of healthcare food (therapy) products by using extractives of cordyceps militaris and cocoons | |
| CN102987405B (en) | Method for preparing health food capsules by using cordyceps militaris and cocoon extracts | |
| TW201425577A (en) | A medium for mycelia of Antrodia Cinnamomea | |
| CN102987408B (en) | Method for extracting nutritional ingredients such as free amino acids from waste cordyceps militaris cocoons | |
| CN105661491A (en) | Peach gum health product and preparation method and application thereof | |
| KR101407231B1 (en) | Method for producing fermented herb extract with high GABA content using Lactobacillus helveticus RMK85 | |
| CN106520579B (en) | A kind of Serratieae fermentation liquid culture medium promoting the gill fungus growth and development of spot jade | |
| CN105167061A (en) | Potato health care product and preparation method and application thereof | |
| CN103667062A (en) | Protective agent for low-temperature preservation of asexual spores of antrodia cinnamomea and protective agent using method | |
| CN108112841A (en) | A kind of cordyceps drink and preparation method thereof | |
| CN106497795A (en) | A kind of Cordyceps funguss seed culture medium containing Fructus Lycii and its application | |
| CN102166029A (en) | Functional drink of multi-bacterium health-keeping extract of mesona chinensis benth | |
| CN102038702A (en) | Anti-ageing application of hesperidin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150916 Termination date: 20161022 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |